scholarly journals Liraglutide Suppresses Obesity and Hyperglycemia Associated with Increases in Hepatic Fibroblast Growth Factor 21 Production in KKAyMice

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Katsunori Nonogaki ◽  
Miki Hazama ◽  
Noriko Satoh
Keyword(s):  
Body Weight ◽  
Blood Glucose ◽  
Growth Factor ◽  
Food Intake ◽  
Fibroblast Growth Factor ◽  
Fold Increase ◽  
Systemic Administration ◽  
Fibroblast Growth ◽  
Glucose Levels ◽  
Blood Glucose Levels

Social isolation contributes to the development of obesity and insulin-independent diabetes in KKAymice. Here we show that systemic administration of liraglutide, a long-acting human glucagon-like peptide-1 (GLP-1) analog, significantly decreased food intake, body weight, and blood glucose levels at 24 h after its administration while having no significant effects on plasma insulin and glucagon levels in individually housed KKAymice. In addition, the systemic administration of liraglutide significantly increased plasma fibroblast growth factor (Fgf) 21 levels (1.8-fold increase) associated with increases in the expression of hepaticFgf21(1.9-fold increase) andPparγ(1.8-fold increase), while having no effects on the expression of hepaticPparαandFgf21in white adipose tissue. Moreover, systemic administration of liraglutide over 3 days significantly suppressed food intake, body weight gain, and hyperglycemia in KKAymice. On the other hand, despite remarkably increased plasma active GLP-1 levels (4.2-fold increase), the ingestion of alogliptin, a selective dipeptidyl peptidase-4 inhibitor, over 3 days had no effects on food intake, body weight, blood glucose levels, and plasma Fgf21 levels in KKAymice. These findings suggest that systemic administration of liraglutide induces hepatic Fgf21 production and suppresses the social isolation-induced obesity and diabetes independently of insulin, glucagon, and active GLP-1 in KKAymice.

scholarly journals The influence of novel GPR119 agonist on body weight, food intake and glucose metabolism in obesity rats provoked high-fat and -carbohydrate diet

2016 ◽  
Vol 62 (1) ◽  
pp. 44-49 ◽  
Author(s):  
Ivan Nikolaevich Tiurenkov ◽  
Denis Vladimirovich Kurkin ◽  
Dmitry Aleksandrovich Bakulin ◽  
Elena Vladimirovna Volotova ◽  
Mikhail Ayratovich Chafeev
Keyword(s):  
Body Weight ◽  
Blood Glucose ◽  
Food Intake ◽  
Glucose Metabolism ◽  
High Fat Diet ◽  
High Fat ◽  
Glucose Levels ◽  
High Carbohydrate ◽  
Blood Glucose Levels ◽  
Gpr119 Agonist

The search for new drugs for the treatment of type 2 diabetes mellitus (T2DM) and obesity remains an urgent problem. Drugs with influence on incretin system are widely used in the treatment of T2DM and obesity, since in addition to the hypoglycemic action of their inherent hypophagic effects. With the discovery of GPR119 receptor, there is the opportunity to pharmacological stimulation of endogenous secretion of incretins. Compound ZB-16 is active GPR119 agonist with IC50=7 nM. Its activation leads to increased secretion of the major incretins (GLP-1 and GIP), which are able to influence glucose metabolism and feeding behavior.Aims — to study the effect of GPR 119 receptor agonist compounds ZB-16 on blood glucose, body weight and food intake in rats with obesity.Material and methods.Male rats with initial weight 390—400 g were fed with high-carbohydrate and high-fat diet. During the next four weeks the animals orally received ZB-16 (1 mg/kg) and metformin (400 mg/kg) and then we assessed the level of water and food consumption, blood glucose levels, and performed oral glucose tolerance test (OGTT).Results.Compound ZB-16 and metformin reduced fasting blood glucose levels and weight of experimental animals, while the control rats gained weight. GPR119 agonist is more pronounced than metformin reduced the area under the curve «glucose of concentration—time» during the OGTT.Conclusions.Novel GPR119 agonist — ZB-16 is comparable to metformin in hypoglycemic and anorexigenic effect in animals with obesity caused high-carbohydrate and high-fat diet.

scholarly journals Antidiabetic effect of Centella asiatica extract (whole plant) in streptozotocin nicotinamide-induced diabetic rats

2019 ◽  
Vol 6 (1) ◽  
pp. 14 ◽  
Author(s):  
Arwin Muhlishoh ◽  
Brian Wasita ◽  
Adi Magna Patriado Nuhriawangsa
Keyword(s):  
Diabetes Mellitus ◽  
Body Weight ◽  
Blood Glucose ◽  
Food Intake ◽  
Centella Asiatica ◽  
Diabetic Rats ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Whole Plant ◽  
One Way Anova

<p><strong>ABSTRAK</strong></p><p><strong>Latar belakang:</strong> Pegagan (<em>Centella asiatica</em>) telah digunakan untuk pengobatan diabetes mellitus. Namun dosis efek anti diabetes ini belum diteliti.</p><p><strong>Tujuan:</strong> Untuk menguji pengaruh variasi dosis ekstrak pegagan (seluruh bagian tanaman) terhadap kadar gula darah, asupan makanan, dan berat badan pada tikus model diabetes mellitus yang diinduksi Streptozotocin Nicotinamide.</p><p><strong>Metode:</strong> Tiga puluh enam tikus Wistar jantan dibagi menjadi enam kelompok perlakuan berbeda: kontrol negatif, kontrol positif, kontrol obat (metformin 45 mg/KgBB/hari), ekstrak pegagan 300 mg/KgBB/hari, 600 mg/KgBB/hari, 1200 mg / KgBB / hari. Pemberian ekstrak pegagan (seluruh bagian tanaman) dan metformin dilakukan selama 28 hari. Kadar gula darah dianalisis menggunakan Glucose Oxidase Phenol Aminoantipyrina Peroxidase (GOD-PAP) sebelum dan sesudah perlakuan. Berat badan dan asupan makanan diukur setiap satu minggu. Data dianalisis menggunakan One Way ANOVA dengan tingkat kepercayaan 95%.</p><p><strong>Hasil:</strong> Pemberian variasi dosis ekstrak pegagan dan metformin secara signifikan menurunkan kadar gula darah, meningkatkan berat badan dan memperbaiki asupan makanan (p = 0,00). Kadar gula darah dan asupan makanan pada kelompok ekstrak pegagan (seluruh bagian tanaman) dosis tinggi (1200 mg / KgBB / hari) lebih baik dibanding kelompok dosis rendah (300 mg / KgBB / hari) dan kelompok dosis sedang (600 mg / hari), dan memiliki efek yang sama dengan tikus yang diobati dengan metformin 45 mg / KgBB / hari.</p><p><strong>Kesimpulan:</strong> Dosis tinggi ekstrak pegagan (1200 mg/KgBB/hari) memiliki efek anti-diabetes yang lebih baik dibanding dosis lain, dan memiliki efek yang sama dengan kontrol obat.</p><p><strong>KATA KUNCI:</strong> gula darah, diabetes, pegagan, Streptozotocin nicotinamide</p><p><strong>ABSTRACT</strong></p><p><strong> Background:</strong> <em>Centella </em>asiatica has been used for healing diabetes mellitus. The dosage of this anti diabetic effect was yet to be explored.</p><p><strong>Objectives:</strong> To examine the effect of the variation in the dosage of C. asiatica extract (whole plant) on blood glucose levels, food intake, and body weight in Streptozotocin Nicotinamide induced diabetic rats.</p><p><strong>Methods:</strong> Thirty-six male Wistar rat were divided into six different groups of treatments: negative control, positive control, medication control (metformin 45 mg/KgBW/day), extract of<em> C. asiatica</em> 300 mg/KgBW/day, 600 mg/KgBW/day, 1200 mg/KgBW/day. Treatments of <em>C. asiatic</em>a extract (whole plant) and metformin was done for 28 days. Blood glucose was analyzed using the Glucose Oxidase Phenol Aminoantipyrina Peroxidase (GOD-PAP) before and after treatment. Body weight and food intake were measured every one week. The data were analyzed using One Way ANOVA with 95% confidence level.</p><p><strong>Results:</strong> The administration of the variation in the dosage of <em>C. asiatica</em> extract and metformin significantly decrease blood glucose levels, increase body weight and improve food intake (p =0.00). Blood glucose level and food intake among high dosage of <em>C. asiatica</em> extract (whole plant) group (1200 mg/KgBW/day) is better than the low dosage group (300 mg/KgBW/day) and moderate dosage group (600 mg/KgBW/ day), and have the same effect with the rats treated with metformin 45 mg/KgBW/day.</p><p><strong>Conclusion:</strong> High dosage of <em>C. asiatica</em> extract (1200 mg/KgBW/day) had a better anti-diabetic effe than other dosages, and had the same effect with the medication control.</p><p><strong>KEYWORDS:</strong> blood glucose,<em> Centella asiatica,</em> diabetes, nicotinamide, Streptozotocin</p>

Evaluation of Glucose and Lipid Lowering Activity of Arganimide A in Normal and Streptozotocin-Induced Diabetic Rats

2019 ◽  
Vol 19 (4) ◽  
pp. 503-510 ◽  
Author(s):  
Mohamed Eddouks ◽  
Farid Khallouki ◽  
Robert W. Owen ◽  
Morad Hebi ◽  
Remy Burcelin
Keyword(s):  
Body Weight ◽  
Blood Glucose ◽  
Oral Administration ◽  
Lipid Profile ◽  
Plasma Cholesterol ◽  
Diabetic Rats ◽  
Lipid Lowering ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Lowering Activity

Aims: Arganimide A (4,4-dihydroxy-3,3-imino-di-benzoic acid) is a compound belonging to a family of aminophenolics found in fruit of Argania spinosa. The purpose of this study was to investigate the glucose and lipid lowering activity of Arganimide A (ARG A). Methods: The effect of a single dose and daily oral administration of Arganimide A (ARG A) on blood glucose levels and plasma lipid profile was tested in normal and streptozotocin (STZ) diabetic rats at a dose of 2 mg/kg body weight. Results: Single oral administration of ARG A reduced blood glucose levels from 26.50±0.61 mmol/L to 14.27±0.73 mmol/L (p<0.0001) six hours after administration in STZ diabetic rats. Furthermore, blood glucose levels were decreased from 5.35±0.30 mmol/L to 3.57±0.17 mmol/L (p<0.0001) and from 26.50±0.61 mmol/L to 3.67±0.29 mmol/L (p<0.0001) in normal and STZ diabetic rats, respectively, after seven days of treatment. Moreover, no significant changes in body weight in normal and STZ rats were shown. According to the lipid profile, the plasma triglycerides levels were decreased significantly in diabetic rats after seven days of ARG treatment (p<0.05). Moreover, seven days of ARG A treatment decreased significantly the plasma cholesterol concentrations (p<0.001). Conclusion: ARG A possesses glucose and lipid-lowering activity in diabetic rats and this natural compound may be beneficial in the treatment of diabetes.

scholarly journals Pharmaceutical hit of anti type 2 Diabetes mellitus on the phenolic extract of Malaka (Phyllanthus emblica L.) flesh

2019 ◽  
Vol 5 (1) ◽  
Author(s):  
Musri Musman ◽  
Mauli Zakia ◽  
Ratu Fazlia Inda Rahmayani ◽  
Erlidawati Erlidawati ◽  
Safrida Safrida
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Body Weight ◽  
Blood Glucose ◽  
Phyllanthus Emblica ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Phenolic Extract

Abstract Background Ethnobotany knowledge in a community has shaped local wisdom in utilizing plants to treat diseases, such as the use of Malaka (Phyllanthus emblica) flesh to treat type 2 diabetes. This study presented evidence that the phenolic extract of the Malaka flesh could reduce blood sugar levels in the diabetic induced rats. Methods The phenolic extract of the P. emblica was administrated to the glucose-induced rats of the Wistar strain Rattus norvegicus for 14 days of treatment where the Metformin was used as a positive control. The data generated were analyzed by the two-way ANOVA Software related to the blood glucose level and by SAS Software related to the histopathological studies at a significant 95% confidence. Results The phenolic extract with concentrations of 100 and 200 mg/kg body weight could reduce blood glucose levels in diabetic rats. The post hoc Dunnet test showed that the administration of the extract to the rats with a concentration of 100 mg/kg body weight demonstrated a very significant decrease in blood glucose levels and repaired damaged cells better than administering the extract at a concentration of 200 mg/kg weight body. Conclusion The evidence indicated that the phenolic extract of the Malaka flesh can be utilized as anti type 2 Diabetes mellitus without damaging other organs.

Food intake rather than blood glucose levels affects the pharmacokinetic profile of insulin aspart in pigs

2021 ◽  
Author(s):  
Anna Katrina Jógvansdóttir Gradel ◽  
Jonas Kildegaard ◽  
Trine Porsgaard ◽  
Jens Lykkesfeldt ◽  
Hanne Hoffman Frølund Refsgaard
Keyword(s):  
Blood Glucose ◽  
Food Intake ◽  
Insulin Aspart ◽  
Pharmacokinetic Profile ◽  
Glucose Levels ◽  
Blood Glucose Levels

scholarly journals Effects of gender and body weight on fibroblast growth factor 23 responsiveness to estimated dietary phosphorus

2016 ◽  
Vol 63 (1.2) ◽  
pp. 58-62 ◽  
Author(s):  
Hiroyuki Ohta ◽  
Masae Sakuma ◽  
Akitsu Suzuki ◽  
Yuuka Morimoto ◽  
Makoto Ishikawa ◽  
...  
Keyword(s):  
Body Weight ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Fibroblast Growth ◽  
Dietary Phosphorus
Sign in / Sign up

Export Citation Format

Share Document